Perelman Vadim 4
Accession 0000921895-18-003075
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 6:25 PM ET
Size
24.1 KB
Accession
0000921895-18-003075
Insider Transaction Report
- Sale
Common Stock
2018-11-13$0.66/sh−391,728$257,561→ 57 total(indirect: By: Baker Street Capital L.P.) - Sale
Common Stock
2018-11-13$0.66/sh−76,896$50,559→ 0 total(indirect: By: Baskerville SPV, L.P.)
- 7,283
Common Stock
- 12,449
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (12,449 underlying) - 9,878
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (9,878 underlying) - 710,074(indirect: By: Baker Street Capital L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (710,074 underlying) - 563,429(indirect: By: Baker Street Capital L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (563,429 underlying) - 131,009(indirect: By: Baskerville SPV, L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (131,009 underlying) - 103,952(indirect: By: Baskerville SPV, L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (103,952 underlying)
- Sale
Common Stock
2018-11-13$0.66/sh−391,728$257,561→ 57 total(indirect: By: Baker Street Capital L.P.) - Sale
Common Stock
2018-11-13$0.66/sh−76,896$50,559→ 0 total(indirect: By: Baskerville SPV, L.P.)
- 563,429(indirect: By: Baker Street Capital L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (563,429 underlying) - 131,009(indirect: By: Baskerville SPV, L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (131,009 underlying) - 103,952(indirect: By: Baskerville SPV, L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (103,952 underlying) - 7,283
Common Stock
- 12,449
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (12,449 underlying) - 9,878
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (9,878 underlying) - 710,074(indirect: By: Baker Street Capital L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (710,074 underlying)
- Sale
Common Stock
2018-11-13$0.66/sh−391,728$257,561→ 57 total(indirect: By: Baker Street Capital L.P.) - Sale
Common Stock
2018-11-13$0.66/sh−76,896$50,559→ 0 total(indirect: By: Baskerville SPV, L.P.)
- 12,449
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (12,449 underlying) - 9,878
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (9,878 underlying) - 563,429(indirect: By: Baker Street Capital L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (563,429 underlying) - 131,009(indirect: By: Baskerville SPV, L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (131,009 underlying) - 103,952(indirect: By: Baskerville SPV, L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (103,952 underlying) - 7,283
Common Stock
- 710,074(indirect: By: Baker Street Capital L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (710,074 underlying)
- Sale
Common Stock
2018-11-13$0.66/sh−391,728$257,561→ 57 total(indirect: By: Baker Street Capital L.P.) - Sale
Common Stock
2018-11-13$0.66/sh−76,896$50,559→ 0 total(indirect: By: Baskerville SPV, L.P.)
- 7,283
Common Stock
- 12,449
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (12,449 underlying) - 9,878
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (9,878 underlying) - 710,074(indirect: By: Baker Street Capital L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (710,074 underlying) - 563,429(indirect: By: Baker Street Capital L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (563,429 underlying) - 131,009(indirect: By: Baskerville SPV, L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (131,009 underlying) - 103,952(indirect: By: Baskerville SPV, L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (103,952 underlying)
- Sale
Common Stock
2018-11-13$0.66/sh−391,728$257,561→ 57 total(indirect: By: Baker Street Capital L.P.) - Sale
Common Stock
2018-11-13$0.66/sh−76,896$50,559→ 0 total(indirect: By: Baskerville SPV, L.P.)
- 7,283
Common Stock
- 12,449
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (12,449 underlying) - 103,952(indirect: By: Baskerville SPV, L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (103,952 underlying) - 9,878
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (9,878 underlying) - 710,074(indirect: By: Baker Street Capital L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (710,074 underlying) - 563,429(indirect: By: Baker Street Capital L.P.)
Series B Warrants
Exercise: $28.25From: 2018-02-09Exp: 2028-02-09→ Common Stock (563,429 underlying) - 131,009(indirect: By: Baskerville SPV, L.P.)
Series A Warrants
Exercise: $20.63From: 2018-02-09Exp: 2028-02-09→ Common Stock (131,009 underlying)
Footnotes (3)
- [F1]This Form 4 is filed jointly by Baker Street Capital L.P. ("BSC LP"), Baskerville SPV, L.P. ("Baskerville SPV"), Baker Street Capital GP, LLC ("BSC GP"), Baker Street Capital Management, LLC ("Baker Street Capital Management") and Vadim Perelman (collectively, the "Reporting Persons"). Each Reporting Person may be deemed to be a member of a Section 13(d) group that owns more than 10% of the Issuer's outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such shares of Common Stock for purposes of Section 16 or for any other purpose.
- [F2]Represents securities owned directly by BSC LP. BSC GP, as the general partner of BSC LP, may be deemed to beneficially own the securities owned by BSC LP. Baker Street Capital Management, as the investment manager of BSC LP, may be deemed to beneficially own the securities owned by BSC LP. Mr. Perelman, as the managing member of each of BSC GP and Baker Street Capital Management, may be deemed to beneficially own the securities owned by BSC LP.
- [F3]Represents securities owned directly by Baskerville SPV. BSC GP, as the general partner of Baskerville SPV, may be deemed to beneficially own the securities owned by Baskerville SPV. Baker Street Capital Management, as the investment manager of Baskerville SPV, may be deemed to beneficially own the securities owned by Baskerville SPV. Mr. Perelman, as the managing member of each of BSC GP and Baker Street Capital Management, may be deemed to beneficially own the securities owned by Baskerville SPV.
Documents
Issuer
DITECH HOLDING Corp
CIK 0001040719
Related Parties
1- filerCIK 0001489810
Filing Metadata
- Form type
- 4
- Filed
- Nov 14, 7:00 PM ET
- Accepted
- Nov 15, 6:25 PM ET
- Size
- 24.1 KB